Literature DB >> 12562720

Bactericidal activity of daptomycin against Streptococcus pneumoniae compared with eight other antimicrobials.

Glenn A Pankuch1, Michael R Jacobs, Peter C Appelbaum.   

Abstract

A spectrum of pneumococci with varying susceptibilities to beta-lactams, macrolides and quinolones was tested for susceptibility to nine antibiotics, including the novel lipopeptide daptomycin. Daptomycin was active against all strains (MIC range </=0.5 mg/L; MIC(50) 0.125 mg/L; MIC(90) 0.25 mg/L). All pneumococci were susceptible to vancomycin, teicoplanin, linezolid and quinupristin/dalfopristin, with MICs < 4.0 mg/L. Time-kill assays with eight strains demonstrated that daptomycin (2 x MIC) was bactericidal in seven of eight strains tested at 24 h, with >90% killing at 1 h.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12562720     DOI: 10.1093/jac/dkg091

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  9 in total

1.  Prevention of brain injury by the nonbacteriolytic antibiotic daptomycin in experimental pneumococcal meningitis.

Authors:  Denis Grandgirard; Christian Schürch; Philippe Cottagnoud; Stephen L Leib
Journal:  Antimicrob Agents Chemother       Date:  2007-03-19       Impact factor: 5.191

2.  Antistaphylococcal activity of dalbavancin, an experimental glycopeptide.

Authors:  Gengrong Lin; Kim Credito; Lois M Ednie; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2005-02       Impact factor: 5.191

3.  Intravitreal daptomycin: a safety and efficacy study.

Authors:  Grant M Comer; John B Miller; Eric W Schneider; Naheed W Khan; David M Reed; Victor M Elner; David N Zacks
Journal:  Retina       Date:  2011-06       Impact factor: 4.256

4.  Combining Ceftriaxone with Doxycycline and Daptomycin Reduces Mortality, Neuroinflammation, Brain Damage, and Hearing Loss in Infant Rat Pneumococcal Meningitis.

Authors:  Lukas Muri; Michael Perny; Jonas Zemp; Denis Grandgirard; Stephen L Leib
Journal:  Antimicrob Agents Chemother       Date:  2019-06-24       Impact factor: 5.191

5.  Antipneumococcal activity of LBM415, a new peptide deformylase inhibitor, compared with those of other agents.

Authors:  Lois M Ednie; Glenn Pankuch; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

6.  Antistaphylococcal activity of CB-181963 (CAB-175), an experimental parenteral cephalosporin.

Authors:  Dianne B Hoellman; Glenn A Pankuch; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

7.  New dosing strategies for an old antibiotic: pharmacodynamics of front-loaded regimens of colistin at simulated pharmacokinetics in patients with kidney or liver disease.

Authors:  Gauri G Rao; Neang S Ly; Curtis E Haas; Samira Garonzik; Alan Forrest; Jurgen B Bulitta; Pamela A Kelchlin; Patricia N Holden; Roger L Nation; Jian Li; Brian T Tsuji
Journal:  Antimicrob Agents Chemother       Date:  2013-12-16       Impact factor: 5.191

8.  In vivo pharmacodynamic activity of daptomycin.

Authors:  Nasia Safdar; David Andes; W A Craig
Journal:  Antimicrob Agents Chemother       Date:  2004-01       Impact factor: 5.191

9.  Capsular serotype and antibiotic resistance of Streptococcus pneumoniae isolates in Malaysia.

Authors:  Cheng-Foh Le; Navindra Kumari Palanisamy; Mohd Yasim Mohd Yusof; Shamala Devi Sekaran
Journal:  PLoS One       Date:  2011-05-16       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.